Conclusions
In low-risk surgical patients with AS, the clinical efficacy of TAVI was
superior to that of SAVR at the 30-day and 1-year follow-up. At the
2-year follow-up, with the exception of the decreased NAF risk, there
was no significant difference in all-cause mortality, cardiovascular
mortality, and life-threatening or significant bleeding. However,
potential late TAVI-associated complications, such as valvular
degeneration and PPI are important clinical concerns that must be
considered when weighing treatment options for AS.